Fig. 1

Among arginine methyltransferases, PRMT5 is a prognostic factor in BC. a PRMT family expression in normal bladder and BLCA from TCGA dataset. Data are presented as the mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, ns: not significant using Wilcoxon test. b BLCA patient’s prognosis according to PRMT family expression in TCGA. DFI: disease-free interval, DSS: disease-specific survival, OS: overall survival, PFS: progression-free survival. c Pearson correlation between PRMT family expression and immune cells evaluated by estimating TCGA BLCA dataset. d ssGSEA scored different immune cell components grouped by PRMT5 expression in TCGA BLCA dataset. Data are presented as the mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, ns: not significant using Wilcoxon test. e Correlation between PRMT family expression in TCGA BLCA dataset and drug sensitivity data provided in the GDSC database. f WGCNA clustered PRMT family gene modules, and KEGG pathway enrichment analysis performed for the most significant gene module associated with PRMT5 expression